VCEL — Vericel Corporation

Summary of Vericel Corporation (VCEL) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Achieved record revenue of $68.4 million, a 30% increase year-over-year, significantly exceeding guidance.
• MACI Revenue: Generated $56.4 million, representing a 22% growth, with a trailing four-quarter growth rate of 23%.
• Burn Care Revenue: Increased over 90% to $12 million, driven by strong Epicel performance ($10.9 million) and NexoBrid ($1.1 million).
• Gross Margin: Improved by over 300 basis points to 72%.
• Adjusted EBITDA: Grew 195% to $9.6 million, with an adjusted EBITDA margin of 14%.
• Free Cash Flow: Generated $15.1 million, ending the quarter with approximately $211 million in cash and investments.

2. Strategic Updates and Business Highlights

• Sales Force Expansion: The newly expanded MACI sales force is effectively driving growth, with record biopsies and implants reported.
• MACI Arthro: Strong early adoption with over half of implants coming from trained surgeons. Positive early clinical data suggests improved patient outcomes.
• FDA Approval: Received FDA approval for MACI commercial manufacturing at a new facility, enhancing production capacity and enabling potential international commercialization.
• BARDA Award: Secured a $197 million award for NexoBrid, with $35 million in initial funding expected to contribute $5-6 million in revenue in the second half of 2026.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased full-year revenue guidance by $10 million to a range of $326 million to $336 million, reflecting strong Q1 performance and expected NexoBrid revenue.
• MACI Revenue Guidance: Revised to $282 million to $288 million for the year, with Q2 expectations of $62.5 million to $63.5 million.
• Burn Care Revenue Guidance: Increased to approximately $44 million to $48 million, up from prior guidance of $36 million to $40 million.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Concerns regarding Agili-C, a competing product, entering the market with better reimbursement situations, although management believes there is minimal overlap with MACI's target patient population.
• Market Environment: Potential headwinds from declining orthopedic procedure volumes and pressures from healthcare access and policy changes, though management has not baked these concerns into guidance.
• Execution Risks: While the sales force expansion has shown promise, maintaining momentum and conversion rates will be critical.

5. Notable Q&A Insights

• Market Segmentation: Management emphasized that MACI remains the clear market leader in cartilage repair, with no significant changes in competitive dynamics.
• Surgeon Feedback: Surgeons have expressed confidence in MACI and MACI Arthro, with no significant concerns about competitive products affecting their usage.
• Clinical Data Importance: The upcoming publication of clinical data on MACI Arthro is expected to catalyze broader adoption, although surgeons are already intuitively aware of the benefits of less invasive procedures.
• Sales Force Performance: The new sales force is reportedly exceeding expectations, with many already beyond breakeven due to effective territory management and execution.

Overall, Vericel's Q1 2026 results reflect strong financial performance and strategic initiatives, positioning the company for continued growth despite potential competitive and market challenges.